Assertio Therapeutics (ASRT) Tops Q4 EPS by 10c

Assertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of $0.30, $0.10 better than the analyst estimate of $0.20. Revenue for the quarter came in at $62.8 million versus the consensus estimate of $60.91 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Crocs upgraded to Overweight at Piper Sandler on North America recovery signs
• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty